Abvc Biopharma (ABVC) Net Margin (2010 - 2025)
Abvc Biopharma's (ABVC) quarterly Net Margin came in at 261.76% in Q3 2025, down 21383.0% on a YoY basis from N/an in Q3 2024, and down 100.05% quarter-over-quarter from 528546.24% in Q4 2024.
Powered by 
Analysis
Abvc Biopharma (ABVC) Net Margin (2010 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has reported Net Margin for 13 consecutive years, with 261.76% the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Net Margin fell 21383.0% year-over-year to 261.76%; the trailing twelve-month figure through Sep 2025 stood at 530.47% (up 201713.0% YoY), and the FY2025 full-year result was 26360.05%, down 2739206.0% from the prior year.
- Net Margin retreated to 261.76% in Q3 2025 per ABVC's latest filing, from 528546.24% in the prior quarter.
- Across five years, Net Margin topped out at 528546.24% in Q4 2024 and bottomed at 242959.67% in Q1 2024.
- Historically, Net Margin has averaged 2617.6% across 5 years, with a median of 1421.74% in 2023.
- The widest YoY moves for Net Margin: up 68798891 bps in 2024, down 24153793 bps in 2024.
- Over 5 years, Net Margin stood at 20988.69% in 2021, then plunged by 104 bps to 825.8% in 2022, then tumbled by 19208 bps to 159442.68% in 2023, then jumped by 431 bps to 528546.24% in 2024, then plunged by 100 bps to 261.76% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 261.76%, 528546.24%, and 47.93% for Q3 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,152.98% |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -261.76% |
| Dec 31, 2024 | 528,546.24% |
| Sep 30, 2024 | -47.93% |
| Jun 30, 2024 | -864.46% |
| Mar 31, 2024 | -242,959.67% |
| Dec 31, 2023 | -159,442.68% |
| Sep 30, 2023 | -20,885.90% |
| Jun 30, 2023 | -37,052.07% |
| Mar 31, 2023 | -1,421.74% |
| Dec 31, 2022 | -825.80% |
| Sep 30, 2022 | -8,764.97% |
| Jun 30, 2022 | -594.19% |
| Mar 31, 2022 | -23,364.93% |
| Dec 31, 2021 | 20,988.69% |
| Sep 30, 2021 | -1,824.75% |
| Jun 30, 2021 | -6,270.68% |
| Mar 31, 2021 | -454.24% |
| Dec 31, 2020 | -7,989.86% |
| Sep 30, 2020 | -1,844.29% |
| Jun 30, 2020 | -816.42% |